[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"depression-and-quality-of-life\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:depression-and-quality-of-life":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,84,114],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100604206","esketamine-nasal-spray-in-real-world-settings-in-treatment-resistant-depression-100604206",false,"NCT07146503","Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression","ESKPSY: Esketamine in Real-World Settings: Clinical Outcomes, Predictors of Response, Life Functioning and Biological Pathways","ESKPSY","Inclusion criteria were: (a) age 18-74, (b) DSM-5 diagnosis of a major depressive episode (MDE), (c) failure to respond to at least 2 prior antidepressant treatments (ADTs), and (d) current treatment with an SSRI or SNRI for which esketamine nasal spray was deemed appropriate.","ALL","18 Years","74 Years",{"count":21,"type":22},100,"ESTIMATED","OBSERVATIONAL","This observational study investigates the use of Esketamine Intranasal Spray in patients with Treatment-Resistant Depression in Real-World Settings. The study aims to evaluate the clinical outcomes, including efficacy and safety, of esketamine treatment. It also explores predictors of treatment response, focusing on biological pathways such as genetics, neuroimaging, and psychophysical measures. Additionally, the study examines how esketamine impacts patients' life functioning, including social and occupational aspects. The goal is to better understand who benefits most from esketamine and how it affects daily life, to improve personalized care for patients with difficult-to-treat depression.",[26,27,28,29,30,31,32,33],"Depression and Quality of Life","Treatment Resistant Depression (TRD)","Anhedonia","Apathy","Anxiety","Cognition","Temperament","Psychiatric Comorbidities","RECRUITING","2026-03-25",{"date":37,"type":38},"2026-03-31","ACTUAL",{"date":40,"type":38},"2022-11-01",{"date":42,"type":22},"2030-08",{"name":44,"class":45},"Riccardo Guglielmo","OTHER",5,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":60,"studyType":23,"phases":4,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100627135","erectile-function-after-pci-in-mi-and-non-mi-patients-100627135","NCT07444697","\"Erectile Function After PCI in MI and Non-MI Patients\"","Erectile Function After Percutaneous Coronary Intervention in Myocardial Infarction and Non-Infarction Patients: A Prospective Comparative Study.","ERECT-PCI","Inclusion Criteria\n\n* Male patients aged 30-75 years\n* Undergoing successful percutaneous coronary intervention (PCI) for one of the following:\n\n  * Acute myocardial infarction (Group 1)\n  * Stable angina (Group 2)\n* Hemodynamically stable after the PCI procedure\n* Survival of the index hospitalization\n* Ability to provide written informed consent\n* Sexually active within the 3 months prior to enrollment\n* Willingness and ability to complete follow-up visits and questionnaires at:\n\n  * Baseline (post-PCI recovery)\n  * 3 months\n  * 6 months Exclusion Criteria\n* Known malignancy (active or recently treated)\n* Neurological disorders affecting erectile function, including:\n\n  * Spinal cord injury\n  * Multiple sclerosis\n  * Parkinson's disease\n* Uncontrolled diabetes mellitus (HbA1c \\> 9%)\n* Presence of more than two chronic systemic diseases, such as:\n\n  * Severe renal disease\n  * Severe hepatic disease\n  * Severe pulmonary disease\n* Polypharmacy, defined as chronic use of more than three daily medications\n* Absence of sexual activity or lack of a sexual partner\n* Refusal or inability to provide informed consent or complete study questionnaires\n* Severe psychiatric illness interfering with study participation\n* Endocrine disorders, including:\n\n  * Untreated hypogonadism\n  * Thyroid disease\n* Major post-PCI complications preventing participation, including:\n\n  * Reinfarction\n  * Stroke\n  * Heart failure",true,"MALE","30 Years","75 Years",{"count":21,"type":22},"6 Months","The goal of this observational study is to assess changes in patients' erectile function after percutaneous coronary intervention (PCI) using a standard IIEF (International Index of Erectile Function) questionnaire at 1, 3, and 6 months post-PCI. By doing this, we try to compare patients' responses to PCI after having a heart attack and stable angina to see the real effect of myocardial infarction on erectile function status in the long term by comparing it with a very similar group.",[63,64,65,30,26],"Erectile Disfunction","Coronary Artery Disease (CAD)","Diabete Mellitus",[67,68,69,70,71,72,73],"erectile disfunction","coronary artery disease","Syntax score","percutaneous coronary intervention","anxiety","Fear","angina","2026-02-24",{"date":76,"type":38},"2026-03-03",{"date":78,"type":38},"2026-01-15",{"date":80,"type":22},"2026-11",{"name":82,"class":45},"Kırıkkale University",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":83},"100614196","effectiveness-of-the-dmhi-and-ops-platform-in-improving-participant-qol-a-randomised-controlled-trial-100614196","NCT07276451","Effectiveness of the DMHI and OPS Platform in Improving Participant QOL: a Randomised Controlled Trial.","Effectiveness of the Digital Mental Health Intervention and Open Peer Support Platform in Improving Participant Quality of Life: a Randomised Controlled Trial.","Inclusion Criteria:\n\n* Aged ≥18 years;\n* No current clinical diagnosis of a mental health disorder;\n* No mental-health treatment or psychotropic medication initiated within the past 3 months;\n* Able to access the internet and provide informed consent.\n\nExclusion Criteria:\n\n* Current engagement with a mental health professional or therapy;\n* Inability to access the DMHI and OPS platform, or inability to provide informed consent;\n* PHQ-9 score ≥15 or GAD-7 score ≥15 at baseline (these participants will be referred to specialist services and excluded from further study participation)\n\nConfirmation of eligibility to participate. To comply with local regulations and ensure participant safety, a qualified and appropriately licensed specialist, affiliated with the institution will participate in screening of the participants recruitment results and carrying out decisions on whether to include or exclude the participant from the study based on degree of severity in the underlying psychological or psychiatric condition. The decision to exclude participants will be made based on safety considerations, need for emergency psychiatric help, compliance assumption and perceived efficacy.\n\nWithdrawal. Participation is voluntary. All enrolled participants are free to withdraw from the study at any time with or without notice to study personnel.\n\nRisk to self and\u002For others. During enrollment and study course, participants will be screened for severity of symptoms. If our participating specialist identifies a risk to self or others, appropriate actions will be taken to contact the authorities and local law representatives according to European and Local Law.\n\nSample size estimates. For two groups and a dichotomous endpoint (improvement or no improvement) and an anticipated incidence of 45% in the intervention group and 75% in the control group, at a 95% confidence level and 5% margin of error, power of 80% and enrolment ratio of 1, a sample size of 82 participants was chosen for this RCT (41 in intervention group, 41 in control group).",{"count":92,"type":22},82,"INTERVENTIONAL",[95],"NA","RCT to evaluate the efficacy of a digital mental health intervention platform with open peer support in improving participant quality of life.",[30,26,98],"Quality of Life",[100,101,102,103],"digital mental health intervention","open peer support","mental health","online support","NOT_YET_RECRUITING","2025-11-28",{"date":107,"type":38},"2025-12-11",{"date":109,"type":22},"2026-01-01",{"date":111,"type":22},"2026-09",{"name":113,"class":45},"Universidade Nova de Lisboa",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":93,"phases":125,"briefSummary":126,"conditions":127,"keywords":132,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":146,"locationsCount":83},"100609240","evaluation-of-dalia-solution-for-depressed-patient-100609240","NCT07211984","Evaluation of Dalia Solution For Depressed Patient","Evaluation of the Clinical and Organizational Impact of the Digital Medical Device Dalia in the Management of Depression","DaliaMonitorin","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patient with a diagnosis of depressive episode, as defined by ICD-11, and with a PHQ-9 score ≥ 15 confirmed by a psychiatrist or general practitioner\n* Patient receiving a first antidepressant treatment (treatment-naïve) OR having had a modification of antidepressant treatment in the two weeks prior to inclusion\n* Patient equipped with a smartphone or a computer or a tablet with internet access\n* Patient affiliated to a health insurance scheme\n* Patient able to read and understand French\n* Patient having signed informed consent\n\nExclusion Criteria:\n\n* Patient under non-cardioselective beta-blocker (carvedilol, labetalol, propranolol, pindolol) and beta-mimetic (salbutamol, terbutaline)\n* Patient with a pacemaker or with a known cardiac arrhythmia\n* Patient with major neurocognitive disorder (e.g., dementia) or psychotic disorders likely to compromise participation in the study\n* Patient hospitalized at the time of inclusion whose discharge is not planned within the next two weeks\n* Patient treated with esketamine\n* Patient with excessive consumption of psychoactive substances (alcohol or drugs), which may interfere with the course or follow-up of the study\n* Patient unable to wear the bracelet during the study due to dermatological conditions\n* Patient under guardianship, curatorship, or legal protection, or any other administrative or judicial measure depriving rights and freedom\n* Patient considered non-autonomous by the investigator\n* Patient already included in another interventional research study\n* Vulnerable persons referred to in Articles L.1121-5 to 8 and L.1122-1-2 of the French Public Health Code are excluded from the study","76 Years",{"count":124,"type":22},644,[95],"The goal of this superiority clinical investigation, prospective, multicenter, controlled, randomized, open-label is to evaluate the clinical impact of the Dalia medical telemonitoring device on the management of depressive patients. The main question it aims to answer is: the percentage of patients with clinically significant improvement at 3 months. A clinically significant improvement is defined as a decrease of at least 5 points from the initial PHQ-9 score AND\u002FOR a PHQ-9 score lower than 15. The threshold of 5 points is the Minimal Clinically Important Difference (MCID) of the PHQ-9 scale",[128,129,130,26,131],"Depression Chronic","Depressed","Depressed Mood","Depression Diagnosis",[133,134,135,136,137,138,139],"Depression","PHQ-9","MADRS","Depressive episode","Anxiety disorder","Antidepressant prescriptions","Smartwatch","2025-10-01",{"date":142,"type":38},"2025-10-08",{"date":144,"type":22},"2025-10-10",{"date":37,"type":22},{"name":147,"class":148},"Dalia Care","INDUSTRY"]